Prana Biotechnology today announced that the New York Academy of Science is hosting a symposium on November 29th titled “Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases”. Dr. Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Prana’s Chief Scientific Advisor, and Dr. Robert Cherny. Prana’s Head of Research, will take part in the symposium.

Prana Biotechnology today announced that it has completed recruitment in the IMAGINE trial, a 12 month Phase II trial testing PBT2, the Company’s drug in development for Alzheimer’s Disease.

Prana Biotechnology today announced that leading scientists discussing the Metal Hypothesis at the New York Academy of Sciences on November 29th at a symposium titled “Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases”, highlighted the promise that therapies like Prana’s PBT2 could offer for sufferers of neurodegenerative diseases.

Prana Biotechnology today announced that the Journal of Huntington’s Disease has in its December, 2012 edition, published data showing the benefits of PBT2 in Huntington Disease*. The paper describes PBT2’s ability to inhibit the development of the symptoms and pathological features of Huntington Disease in pre-clinical transgenic animal models.

Prana Biotechnology today announced that it has completed recruitment in the Reach2HD Phase IIa clinical trial using PBT2 in patients with Huntington Disease (HD).

Prana Biotechnology today announced that the New York Academy of Sciences eBriefing which provides information and video footage of the symposium which took place on November 29th titled “Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases” is now available for viewing by the public by going to: www.nyas.org/MetalsandAD-eB. The eBriefing features multimedia presentations of speakers’ slides and audio, written meeting summary, and links to related resources.

Prana Biotechnology today announced that Prana’s Chairman and CEO, Geoffrey Kempler, will provide a company overview and update at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 2:50 pm ET at The Boston Marriott Copley Place in Boston, MA.

Prana Biotechnolo today announced the upcoming presentation of new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment. The tau protein, along with the Abeta protein, are the two major proteins associated with Alzheimer’s Disease.

Prana Biotechnology today announced that PBT434, Prana’s lead drug candidate for Parkinson’s disease (PD) and movement disorders, will be presented at two international conferences in March. The key finding to be reported is that PBT434 reduces the aggregation and accumulation of a key protein (alpha- synuclein) in multiple transgenic animal models of the disease.

Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment.